| Complication/event . | CD4+ T-cell lymphopenia (N = 27) . | Missing data . | Controls (N = 54) . | Missing data . | P-value . |
|---|---|---|---|---|---|
| Neoplastic and infectious complications [n (%)] | |||||
| Malignancies | 13 (50) | 1 | 16 (29.6) | 0 | 0.047 |
| Skin cancer | 9 (34.6) | 1 | 8 (14.8) | 0 | 0.069 |
| PTLD | 3 (11.5) | 1 | 2 (3.7) | 0 | |
| Infectious complications | 23 (88.5) | 1 | 40 (74.1) | 0 | 0.140 |
| Graft pyelonephritis | 9 (34.6) | 1 | 15 (27.8) | 0 | |
| Pneumonia | 5 (19.2) | 1 | 5 (9.3) | 0 | |
| Sinusitis | 2 (7.7) | 1 | 5 (9.3) | 0 | |
| Angiocholitis, sigmoiditis, cholecystitis | 2 (7.7) | 1 | 5 (9.3) | 0 | |
| Opportunistic infection | 6 (22.2) | 1 | 7 (13.0) | 0 | 0.290 |
| Cardiovascular risk factors and events [n (%)] | |||||
| Hypertension | 22 (84.6) | 1 | 38 (71.7) | 1 | 0.280 |
| Diabetes mellitus | 5 (19.2) | 1 | 13 (25) | 2 | 0.570 |
| Treated dyslipidemia | 13 (50) | 1 | 40 (75.5) | 1 | 0.026 |
| Cardiovascular events | 9 (34.6) | 1 | 15 (28.3) | 1 | 0.490 |
| Complication/event . | CD4+ T-cell lymphopenia (N = 27) . | Missing data . | Controls (N = 54) . | Missing data . | P-value . |
|---|---|---|---|---|---|
| Neoplastic and infectious complications [n (%)] | |||||
| Malignancies | 13 (50) | 1 | 16 (29.6) | 0 | 0.047 |
| Skin cancer | 9 (34.6) | 1 | 8 (14.8) | 0 | 0.069 |
| PTLD | 3 (11.5) | 1 | 2 (3.7) | 0 | |
| Infectious complications | 23 (88.5) | 1 | 40 (74.1) | 0 | 0.140 |
| Graft pyelonephritis | 9 (34.6) | 1 | 15 (27.8) | 0 | |
| Pneumonia | 5 (19.2) | 1 | 5 (9.3) | 0 | |
| Sinusitis | 2 (7.7) | 1 | 5 (9.3) | 0 | |
| Angiocholitis, sigmoiditis, cholecystitis | 2 (7.7) | 1 | 5 (9.3) | 0 | |
| Opportunistic infection | 6 (22.2) | 1 | 7 (13.0) | 0 | 0.290 |
| Cardiovascular risk factors and events [n (%)] | |||||
| Hypertension | 22 (84.6) | 1 | 38 (71.7) | 1 | 0.280 |
| Diabetes mellitus | 5 (19.2) | 1 | 13 (25) | 2 | 0.570 |
| Treated dyslipidemia | 13 (50) | 1 | 40 (75.5) | 1 | 0.026 |
| Cardiovascular events | 9 (34.6) | 1 | 15 (28.3) | 1 | 0.490 |
| Complication/event . | CD4+ T-cell lymphopenia (N = 27) . | Missing data . | Controls (N = 54) . | Missing data . | P-value . |
|---|---|---|---|---|---|
| Neoplastic and infectious complications [n (%)] | |||||
| Malignancies | 13 (50) | 1 | 16 (29.6) | 0 | 0.047 |
| Skin cancer | 9 (34.6) | 1 | 8 (14.8) | 0 | 0.069 |
| PTLD | 3 (11.5) | 1 | 2 (3.7) | 0 | |
| Infectious complications | 23 (88.5) | 1 | 40 (74.1) | 0 | 0.140 |
| Graft pyelonephritis | 9 (34.6) | 1 | 15 (27.8) | 0 | |
| Pneumonia | 5 (19.2) | 1 | 5 (9.3) | 0 | |
| Sinusitis | 2 (7.7) | 1 | 5 (9.3) | 0 | |
| Angiocholitis, sigmoiditis, cholecystitis | 2 (7.7) | 1 | 5 (9.3) | 0 | |
| Opportunistic infection | 6 (22.2) | 1 | 7 (13.0) | 0 | 0.290 |
| Cardiovascular risk factors and events [n (%)] | |||||
| Hypertension | 22 (84.6) | 1 | 38 (71.7) | 1 | 0.280 |
| Diabetes mellitus | 5 (19.2) | 1 | 13 (25) | 2 | 0.570 |
| Treated dyslipidemia | 13 (50) | 1 | 40 (75.5) | 1 | 0.026 |
| Cardiovascular events | 9 (34.6) | 1 | 15 (28.3) | 1 | 0.490 |
| Complication/event . | CD4+ T-cell lymphopenia (N = 27) . | Missing data . | Controls (N = 54) . | Missing data . | P-value . |
|---|---|---|---|---|---|
| Neoplastic and infectious complications [n (%)] | |||||
| Malignancies | 13 (50) | 1 | 16 (29.6) | 0 | 0.047 |
| Skin cancer | 9 (34.6) | 1 | 8 (14.8) | 0 | 0.069 |
| PTLD | 3 (11.5) | 1 | 2 (3.7) | 0 | |
| Infectious complications | 23 (88.5) | 1 | 40 (74.1) | 0 | 0.140 |
| Graft pyelonephritis | 9 (34.6) | 1 | 15 (27.8) | 0 | |
| Pneumonia | 5 (19.2) | 1 | 5 (9.3) | 0 | |
| Sinusitis | 2 (7.7) | 1 | 5 (9.3) | 0 | |
| Angiocholitis, sigmoiditis, cholecystitis | 2 (7.7) | 1 | 5 (9.3) | 0 | |
| Opportunistic infection | 6 (22.2) | 1 | 7 (13.0) | 0 | 0.290 |
| Cardiovascular risk factors and events [n (%)] | |||||
| Hypertension | 22 (84.6) | 1 | 38 (71.7) | 1 | 0.280 |
| Diabetes mellitus | 5 (19.2) | 1 | 13 (25) | 2 | 0.570 |
| Treated dyslipidemia | 13 (50) | 1 | 40 (75.5) | 1 | 0.026 |
| Cardiovascular events | 9 (34.6) | 1 | 15 (28.3) | 1 | 0.490 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
